David Shih, MD
Gastroenterology · Las Vegas, NVNPI 1992895601
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.2%), speaking fees and education — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Redhill Biopharma Inc. at 33.0% of the total. Reporting peaked in 2021 at $9,243 and has fallen 80.4% since, to $1,810 in 2025. Among gastroenterology clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 771 payments — averaging $33.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Redhill Biopharma Inc.$9K
- AbbVie$5K
- Ferring Pharmaceuticals Inc.$4K
- Johnson & Johnson$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $5K from 31 others
What the payments were for
- Speaking & faculty fees$11,65245%
- Food & beverage$14,06854%
- Education$2371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Redhill Biopharma Inc. | 37 | $8,566 |
| AbbVie | 248 | $4,610 |
| Ferring Pharmaceuticals Inc. | 31 | $4,424 |
| Johnson & Johnson(2 entities) | 76 | $1,112 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 80 | $1,075 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $1,043 |
| Gilead | 35 | $979 |
| Sanofi | 32 | $659 |
| Aimmune Therapeutics, Inc. | 26 | $487 |
| Ironwood Pharmaceuticals, Inc | 23 | $410 |
| Nestle Healthcare Nutrition Inc. | 21 | $389 |
| Braintree Laboratories, Inc. | 21 | $341 |
| QOL Medical, LLC | 16 | $295 |
| Merck | 9 | $158 |
| Orphalan Inc | 5 | $136 |
| Pfizer | 6 | $128 |
| Ardelyx, Inc. | 6 | $115 |
| Bristol Myers Squibb | 6 | $113 |
| Alfasigma USA, Inc. | 5 | $105 |
| UCB, Inc. | 7 | $102 |
| Shionogi Inc | 4 | $81 |
| Phathom Pharmaceuticals, Inc. | 4 | $70 |
| Boston Scientific | 1 | $64 |
| Enterra Medical, Inc. | 1 | $64 |
| Intercept Pharmaceuticals, Inc. | 4 | $59 |
| Celltrion USA Inc. | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Lilly USA, LLC | 2 | $49 |
| Organon | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Shire North American Group Inc | 2 | $28 |
| Daiichi Sankyo Inc. | 2 | $25 |
| Madrigal Pharmaceuticals | 1 | $24 |
| AstraZeneca | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Endogastric Solutions, Inc | 1 | $16 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,958 in reported general payments places this provider in the 90th percentile of 103 gastroenterology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 12 | $71,873 |
| CreonLipase/Protease/Amylase | 19 | $37,020 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 217 | $36,969 |
| LinzessLinaclotide | 41 | $32,709 |
| IbsrelaTenapanor Hcl | 13 | $25,960 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 76 | $12,303 |
| Omeprazole | 856 | $10,117 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 110 | $7,141 |
| Mesalamine ErMesalamine | 22 | $5,910 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 38 | $5,750 |
| Mesalamine | 21 | $3,911 |
| Dexlansoprazole DrDexlansoprazole | 16 | $3,499 |
| Lubiprostone | 13 | $3,208 |
| Ursodiol | 19 | $2,337 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 19 | $2,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Creon, Linzess | $4,610 | $141,60272 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $4,424 | $36,969217 claims |
| Ardelyx, Inc.Ibsrela | $115 | $25,96013 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $341 | $14,61195 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $1,075 | $5,75038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 103 gastroenterology providers in Nevada.
Other gastroenterology in Las Vegas
- Christian StoneLas Vegas$1.1M
- James HanLas Vegas$47K
- Filippo CremoniniLas Vegas$36K
- Vijay JayaramanLas Vegas$28K
- Gary ChenLas Vegas$27K
- Noel FajardoLas Vegas$22K
- Frank FarisLas Vegas$14K
- Tarek AmmarLas Vegas$14K
- Eladio CarreraLas Vegas$13K
- Uday SaraiyaLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.